Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies

• Mark C. Genovese,
• Patrick Durez,
• Roy Fleischmann,
• Yoshiya Tanaka,
• Daniel Furst,
• Hisashi Yamanaka ,
• Elena Korneva,
• Igor Vasyutin,
• Tsutomu Takeuchi

Affiliations

Mark C. Genovese

Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA

Patrick Durez

Pôle de Pathologies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium

Roy Fleischmann

Department of Medicine, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, Texas, USA

Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health School of Medicine, Fukuoka, Japan

Daniel Furst

The Geffen School of Medicine, University of California, Los Angeles, California, USA

Hisashi Yamanaka

Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Elena Korneva

JSC “R-Pharm”, Moscow, Russia

Igor Vasyutin

JSC “R-Pharm”, Moscow, Russia

Tsutomu Takeuchi

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan